Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL9551172 | 0.97 | LMNA (0.48) | TSHRLMNACHRM2CHRM4CHRM5 | |
| SCHEMBL2547540 | 0.90 | LMNA (0.57) | TSHRLMNACHRM2CHRM4CHRM5 | |
| SCHEMBL438344 | 0.88 | — | — | |
| SCHEMBL30525718 | 0.87 | LMNA (0.62) | TSHRLMNACHRM2CHRM4CHRM5 | |
| Ammonia Solution, Strong SCHEMBL27495970 | 0.85 | — | — | |
| Water SCHEMBL2781587 | 0.85 | — | — | |
| Ethylene SCHEMBL21679941 | 0.84 | TSHR (0.52) | TSHRLMNACHRM2CHRM4CHRM5 | |
| Formaldehyde SCHEMBL4454552 | 0.84 | TSHR (0.52) | TSHRLMNACHRM2CHRM4CHRM5 | |
| SCHEMBL5246994 | 0.84 | MEN1 (0.55) | TSHRLMNACHRM2CHRM4CHRM5 | |
| SCHEMBL28536719 | 0.84 | MEN1 (0.55) | TSHRLMNACHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053212-A1 | METHODS OF TREATING HUMANS UNDERGOING INJECTION OF A CONTRAST AGENT | SHIVA BIOMEDICAL, LLC (US) | 2012-03-01 | — | — | US | disclosed |
| EP-2129280-A2 | METHODS OF DIAGNOSING AND ALLEVIATING GADOLINIUM TOXICITY | Cormedix Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| US-20080293779-A1 | Methods of treating humans undergoing injection of a contrast agent | SHIVA BIOMEDICAL, LLC (US) | 2008-11-27 | — | — | US | disclosed |
| EP-1173757-B1 | DIAGNOSIS OF HUMAN KIDNEY DISEASES | SHIVA BIOMEDICAL LLC (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20080138440-A1 | Methods of diagnosing and alleviating gadolinium toxicity | CORMEDIX INC. (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008066862-A2 | METHODS OF DIAGNOSING AND ALLEVIATING GADOLINIUM TOXICITY | CORMEDIX INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| US-20070238760-A1 | Diagnosis and treatment of human kidney diseases | SHIVA BIOMEDICAL, LLC | 2007-10-11 | — | — | US | disclosed |
| EP-1819334-A1 | METHODS OF TREATING ERYTHROPOIETIN-RESISTANCE | Shiva Biomedical, LLC (US) | 2007-08-22 | — | — | EP | disclosed |
| US-7235542-B2 | Diagnosis and treatment of human kidney diseases | SHIVA BIOMEDICAL, LLC (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1776118-A2 | IRON CHELATORS FOR TREATING RADIOCONTRAST-ASSOCIATED RENAL DYSFUNCTION | Shiva Biomedical, LLC (US) | 2007-04-25 | — | — | EP | disclosed |
| US-20050026814-A1 | Diagnosis and treatment of human kidney diseases | SHIVA BIOMEDICAL, LLC (US) | 2005-02-03 | — | — | US | disclosed |
| US-20040192663-A1 | Diagnosis and treatment of human kidney diseases | SHIVA BIOMEDICAL, LLC (US) | 2004-09-30 | — | — | US | disclosed |
| US-20040121422-A1 | Diagnosis and treatment of human kidney diseases | SHIVA BIOMEDICAL, LLC | 2004-06-24 | — | — | US | disclosed |
| US-20040116401-A1 | Diagnosis and treatment of human kidney diseases | SHIVA BIOMEDICAL, LLC | 2004-06-17 | — | — | US | disclosed |
| WO-2000065346-A9 | DIAGNOSIS OF HUMAN KIDNEY DISEASES | SHIVA BIOMEDICAL LLC (US) | 2002-06-06 | — | — | WO | disclosed |
| EP-1173757-A1 | DIAGNOSIS OF HUMAN KIDNEY DISEASES | Shiva Biomedical, LLC (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000065346-A1 | DIAGNOSIS OF HUMAN KIDNEY DISEASES | SHIVA BIOMEDICAL, LLC (US) | 2000-11-02 | — | — | WO | disclosed |
| US-5424057-A | Medical diagnosis | CIBA-GEIGY CORP. (US) | 1995-06-13 | — | — | US | disclosed |
| US-5328992-A | Compounds used as metal chelators and for medical diagnosis | CIBA-GEIGY CORP. (US) | 1994-07-12 | — | — | US | disclosed |
| US-5185368-A | Complex with trivalent metal ions; medical diagnosis and therapy | CIBA-GEIGY CORPORATION (US) | 1993-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238760-A1 | Diagnosis and treatment of human kidney diseases | SLC40A1, SLC14A1, TFRC | TSHR 2094/4885LMNA 2763/4885CHRM2 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.